001     301763
005     20250828084755.0
024 7 _ |a 10.1016/j.eururo.2025.05.020
|2 doi
024 7 _ |a pmid:40461322
|2 pmid
024 7 _ |a 0302-2838
|2 ISSN
024 7 _ |a 1421-993X
|2 ISSN
024 7 _ |a 1873-7560
|2 ISSN
024 7 _ |a altmetric:177837077
|2 altmetric
037 _ _ |a DKFZ-2025-01143
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Al-Monajjed, Rouvier
|0 P:(DE-He78)555d0aa06e51f29f46d788ff54fc6811
|b 0
|e First author
|u dkfz
245 _ _ |a Prostate Cancer Detection in Younger Men: A Comparative Analysis of Systematic and Magnetic Resonance Imaging-targeted Biopsy in the PROBASE Trial.
260 _ _ |a Amsterdam [u.a.]
|c 2025
|b Elsevier Science
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1756363611_18474
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a #EA:C130#LA:C130# / 2025 Sep;88(3):240-244
520 _ _ |a The optimal approach for prostate cancer (PC) screening, including the ideal starting age and most effective diagnostic method, remains under investigation. We evaluated the diagnostic performance of magnetic resonance imaging (MRI)-targeted biopsy (TBx) and systematic biopsy (SBx) in detecting clinically significant PC (csPC) in men aged 45-50 yr in PROBASE, a prospective, randomized trial of a risk-adapted screening strategy. A total of 525 participants with elevated prostate-specific antigen (≥3 ng/ml) underwent MRI followed by biopsy. Of the 209 PC cases detected, 148 (71%) were csPC. SBx identified 94% of csPC cases, while TBx detected 74% (p ≤ 0.05). SBx also diagnosed significantly more low-grade PCs than TBx (p < 0.001). These findings suggest that relying solely on MRI-TBx may lead to underdiagnosis of csPC. Combining SBx with TBx remains the most effective strategy for early detection of PC in young men undergoing screening. Future research should explore optimization strategies to reduce unnecessary biopsies while maintaining high detection rates for csPC. This trial is registered on the ISRCTN registry as ISRCTN37591328 (https://www.isrctn.com/ISRCTN37591328). The study protocol can be accessed at https://doi.org/10.1016/j.eururo.2013.05.022.
536 _ _ |a 313 - Krebsrisikofaktoren und Prävention (POF4-313)
|0 G:(DE-HGF)POF4-313
|c POF4-313
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
650 _ 7 |a Fusion biopsy
|2 Other
650 _ 7 |a Magnetic resonance imaging
|2 Other
650 _ 7 |a Prostate cancer
|2 Other
650 _ 7 |a Prostate-specific antigen
|2 Other
650 _ 7 |a Risk-adapted screening
|2 Other
650 _ 7 |a Ultrasound
|2 Other
700 1 _ |a Boschheidgen, Matthias
|b 1
700 1 _ |a Lakes, Jale
|b 2
700 1 _ |a Krilaviciute, Agne
|0 P:(DE-He78)78a9df7108a5b079145be1cb1ab6a315
|b 3
|u dkfz
700 1 _ |a Radtke, Jan-Philipp
|b 4
700 1 _ |a Schlemmer, Heinz-Peter
|0 P:(DE-He78)3d04c8fee58c9ab71f62ff80d06b6fec
|b 5
|u dkfz
700 1 _ |a Bonekamp, David
|0 P:(DE-He78)ea098e4d78abeb63afaf8c25ec6d6d93
|b 6
|u dkfz
700 1 _ |a Herkommer, Kathleen
|b 7
700 1 _ |a Jahnen, Matthias
|b 8
700 1 _ |a Gschwend, Jürgen E
|b 9
700 1 _ |a Düx, Daniel
|b 10
700 1 _ |a Wacker, Frank
|b 11
700 1 _ |a Makowski, Marcus R
|b 12
700 1 _ |a Sauter, Andreas
|b 13
700 1 _ |a Kuczyk, Markus A
|b 14
700 1 _ |a Harke, Nina
|b 15
700 1 _ |a Debus, Jürgen
|b 16
700 1 _ |a Grott, Christoph
|b 17
700 1 _ |a Arsov, Christian
|b 18
700 1 _ |a Seibold, Petra
|0 P:(DE-He78)fd17a8dbf8d08ea5bb656dfef7398215
|b 19
|u dkfz
700 1 _ |a Hadaschik, Boris
|0 P:(DE-HGF)0
|b 20
700 1 _ |a Giesel, Frederik
|b 21
700 1 _ |a Kristiansen, Glenn
|b 22
700 1 _ |a Antoch, Gerald
|b 23
700 1 _ |a Becker, Nikolaus
|0 P:(DE-He78)1573258b58c33f1922ca9719d0c8c4ab
|b 24
|u dkfz
700 1 _ |a Kaaks, Rudolf
|0 P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a
|b 25
|u dkfz
700 1 _ |a Schimmöller, Lars
|b 26
700 1 _ |a Albers, Peter
|0 P:(DE-He78)f84639cbc39bc20ecda8d00e6de97578
|b 27
|e Last author
|u dkfz
773 _ _ |a 10.1016/j.eururo.2025.05.020
|g p. S0302283825002982
|0 PERI:(DE-600)1482253-2
|n 3
|p 240-244
|t European urology
|v 88
|y 2025
|x 0302-2838
909 C O |p VDB
|o oai:inrepo02.dkfz.de:301763
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 0
|6 P:(DE-He78)555d0aa06e51f29f46d788ff54fc6811
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 3
|6 P:(DE-He78)78a9df7108a5b079145be1cb1ab6a315
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 5
|6 P:(DE-He78)3d04c8fee58c9ab71f62ff80d06b6fec
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 6
|6 P:(DE-He78)ea098e4d78abeb63afaf8c25ec6d6d93
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 19
|6 P:(DE-He78)fd17a8dbf8d08ea5bb656dfef7398215
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 20
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 24
|6 P:(DE-He78)1573258b58c33f1922ca9719d0c8c4ab
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 25
|6 P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 27
|6 P:(DE-He78)f84639cbc39bc20ecda8d00e6de97578
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-313
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Krebsrisikofaktoren und Prävention
|x 0
914 1 _ |y 2025
915 _ _ |a National-Konsortium
|0 StatID:(DE-HGF)0430
|2 StatID
|d 2024-12-20
|w ger
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b EUR UROL : 2022
|d 2024-12-20
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2024-12-20
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2024-12-20
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2024-12-20
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2024-12-20
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2024-12-20
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2024-12-20
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2024-12-20
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2024-12-20
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2024-12-20
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2024-12-20
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2024-12-20
915 _ _ |a IF >= 20
|0 StatID:(DE-HGF)9920
|2 StatID
|b EUR UROL : 2022
|d 2024-12-20
920 2 _ |0 I:(DE-He78)C130-20160331
|k C130
|l Personalisierte Früherkennung des Prostatakarzinoms
|x 0
920 1 _ |0 I:(DE-He78)C130-20160331
|k C130
|l Personalisierte Früherkennung des Prostatakarzinoms
|x 0
920 1 _ |0 I:(DE-He78)E010-20160331
|k E010
|l E010 Radiologie
|x 1
920 1 _ |0 I:(DE-He78)ED01-20160331
|k ED01
|l DKTK Koordinierungsstelle Essen/Düsseldorf
|x 2
920 1 _ |0 I:(DE-He78)C020-20160331
|k C020
|l Epidemiologie von Krebs
|x 3
920 0 _ |0 I:(DE-He78)C130-20160331
|k C130
|l Personalisierte Früherkennung des Prostatakarzinoms
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)C130-20160331
980 _ _ |a I:(DE-He78)E010-20160331
980 _ _ |a I:(DE-He78)ED01-20160331
980 _ _ |a I:(DE-He78)C020-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21